{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.24","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"}],"units":"Participants"}],"title":"Baseline BDI-II Score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.91","value":"-2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"}],"units":"Participants"}],"title":"Change from Baseline in BDI-II Score at Week 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"}],"units":"Participants"}],"description":"The BDI-II is a 21-question self-report inventory that measures depression. Each answer is scored with values of 0 to 3. The total score ranges from 0 to 63. Scores of 0 to 13 indicate minimal depression, 14 to 19; mild depression; 20 to 28; moderate depression; 29 to 63; severe depression.","dispersionType":"Standard Deviation","groups":[{"description":"Patients will receive relacorilant increased sequentially from 100 mg once daily to a maximum dose of 400 mg once daily.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (OL Phase)"}],"paramType":"MEAN","populationDescription":"The analysis population was patients in the mITT-OL Population.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 22 (end of OL Phase)","title":"Change in Beck Depression Inventory-II (BDI-II) Score During the OL Phase","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"score on a scale"}